Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Primary membranous nephropathy in the era of autoantibodies and biological thera...
Journal Information
Vol. 157. Issue 3.
Pages 121-129 (August 2021)
Download PDF
More article options
Vol. 157. Issue 3.
Pages 121-129 (August 2021)
Primary membranous nephropathy in the era of autoantibodies and biological therapies
Nefropatía membranosa primaria en la era de los autoanticuerpos y de las terapias biológicas
Jorge Enrique Rojas-Riveraa,b,c,d,
Corresponding author

Corresponding author.
, Alberto Ortiz Arduánb,c,d
a Unidad de Enfermedades Glomerulares y Autoinmunes
b Servicio de Nefrología e Hipertensión, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
c Grupo Español de Estudio en Enfermedades Glomerulares (GLOSEN), Spain
d Departamento de Medicina, Universidad Autónoma de Madrid, Madrid, Spain
Article information
Full Text
Download PDF
Figures (3)
Show moreShow less
Tables (3)
Table 1. Diseases associated with membranous nephropathy.
Table 2. Key histopathological findings to differentiate primary from secondary membranous nephropathy.
Table 3. Comparative findings of the main randomized clinical trials of rituximab in primary membranous nephropathy.
Show moreShow less

Primary membranous nephropathy is an autoimmune kidney disease and the most common cause of nephrotic syndrome in adults. About 70%–80% of cases are caused by anti-PLA2R antibodies. Its association with anti-THSD7A antibodies and other autoantibodies has also been described. Recent pilot studies and clinical trials have shown that several biological agents targeting autoantibody-producing cells are effective in controlling the disease with an acceptable safety profile.

In this narrative review, we update key concepts about the pathogenesis, autoantibody-based diagnosis, and kidney biopsy findings in primary membranous nephropathy. In addition, we propose a diagnostic and therapeutic algorithm, including guidance on monitoring the response to therapy. We compare the efficacy and safety of currently available treatments, including rituximab and new biological agents, and identify unmet clinical needs.

Membranous nephropathy
Nephrotic syndrome
Anti-PLA2R antibodies
Immunosuppressive therapy
Anti-CD20 treatment

La nefropatía membranosa primaria es una enfermedad renal autoinmune y la causa más frecuente de síndrome nefrótico en el adulto. El 70 a 80% de los casos están causados por anticuerpos anti-PLA2R y en menor porcentaje por anticuerpos anti-THSD7A y otros autoanticuerpos recientemente descubiertos, cuya confirmación y validación clínica están pendientes. Estudios piloto y ensayos clínicos recientes han mostrado que diversos agentes biológicos dirigidos frente a las células productoras de autoanticuerpos son eficaces en el control de la enfermedad con un mejor perfil de seguridad que los inmunosupresores inespecíficos clásicos.

En esta revisión narrativa actualizamos conceptos claves sobre la patogenia y el diagnóstico mediante autoanticuerpos y biopsia renal de la nefropatía membranosa primaria. Además, proponemos un algoritmo diagnóstico, terapéutico y de seguimiento de la respuesta al tratamiento, comparamos la eficacia y seguridad de los tratamientos actualmente disponibles, incluyendo el rituximab y nuevas terapias biológicas, e identificamos necesidades clínicas no cubiertas.

Palabras clave:
Nefropatía membranosa primaria
Síndrome nefrótico
Anticuerpos anti-PLA2R
Terapia inmunosupresora
Tratamiento anti-CD20


These are the options to access the full texts of the publication Medicina Clínica (English Edition)

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe to

Medicina Clínica (English Edition)

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos